SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Sold by J. Goldman & Co LP

J. Goldman & Co LP cut its stake in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) by 15.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 53,503 shares of the company’s stock after selling 9,733 shares during the period. J. Goldman & Co LP owned approximately 0.07% of SpringWorks Therapeutics worth $1,933,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in SWTX. Boxer Capital Management LLC acquired a new position in shares of SpringWorks Therapeutics in the fourth quarter valued at approximately $123,620,000. Capital International Investors grew its holdings in shares of SpringWorks Therapeutics by 92.7% in the fourth quarter. Capital International Investors now owns 2,361,746 shares of the company’s stock valued at $85,330,000 after purchasing an additional 1,136,079 shares in the last quarter. Pictet Asset Management Holding SA grew its holdings in shares of SpringWorks Therapeutics by 24.2% in the fourth quarter. Pictet Asset Management Holding SA now owns 2,391,412 shares of the company’s stock valued at $86,402,000 after purchasing an additional 465,494 shares in the last quarter. Principal Financial Group Inc. grew its holdings in shares of SpringWorks Therapeutics by 102.5% in the third quarter. Principal Financial Group Inc. now owns 918,445 shares of the company’s stock valued at $29,427,000 after purchasing an additional 464,903 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of SpringWorks Therapeutics by 6.6% in the fourth quarter. Vanguard Group Inc. now owns 7,158,871 shares of the company’s stock valued at $258,650,000 after purchasing an additional 445,593 shares in the last quarter.

Insider Transactions at SpringWorks Therapeutics

In other news, CEO Saqib Islam sold 10,672 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $59.92, for a total transaction of $639,466.24. Following the completion of the sale, the chief executive officer now owns 1,063,953 shares in the company, valued at approximately $63,752,063.76. The trade was a 0.99% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Bhavesh Ashar sold 1,016 shares of the company’s stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $61.19, for a total transaction of $62,169.04. Following the completion of the sale, the insider now owns 62,053 shares of the company’s stock, valued at approximately $3,797,023.07. This trade represents a 1.61% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 158,016 shares of company stock worth $9,102,946. 7.83% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research analysts recently weighed in on SWTX shares. Cowen cut shares of SpringWorks Therapeutics to a “hold” rating in a report on Tuesday, April 29th. Guggenheim cut shares of SpringWorks Therapeutics from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $77.00 to $47.00 in a report on Monday, April 28th. HC Wainwright restated a “neutral” rating and issued a $47.00 price objective (down previously from $74.00) on shares of SpringWorks Therapeutics in a report on Wednesday, April 30th. Evercore ISI downgraded shares of SpringWorks Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 28th. Finally, Wedbush reiterated a “neutral” rating and issued a $47.00 price target (down previously from $81.00) on shares of SpringWorks Therapeutics in a research note on Monday, April 28th. Seven research analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $52.57.

SpringWorks Therapeutics Stock Up 0.1%

Shares of SpringWorks Therapeutics stock opened at $46.26 on Monday. SpringWorks Therapeutics, Inc. has a 52-week low of $28.21 and a 52-week high of $62.00. The company has a 50 day moving average of $44.35 and a 200 day moving average of $41.76. The company has a market capitalization of $3.47 billion, a P/E ratio of -13.29 and a beta of 0.77.

SpringWorks Therapeutics (NASDAQ:SWTX) last issued its quarterly earnings results on Friday, May 9th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.81) by ($0.30). The firm had revenue of $49.09 million during the quarter, compared to analysts’ expectations of $64.19 million. SpringWorks Therapeutics had a negative return on equity of 46.74% and a negative net margin of 134.73%. As a group, research analysts anticipate that SpringWorks Therapeutics, Inc. will post -2.05 earnings per share for the current fiscal year.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.